Protocol Number: EYP-1901-201
Primary Investigator: Thomas Aaberg Jr., M.D.
EyePoint Pharmaceuticals, Inc. has begun a study of an investigational drug (also known as the “study drug”) called EYP-1901 as a possible treatment for Wet AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Medicines Agency (EMA), or others. EYP-1901 is an insert that is placed inside your eye, it slowly dissolves over time to give a controlled release of this study drug called Vorolanib. Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor (PDGF) are the proteins found in the eyes that trigger the protein pathways, leading to Wet AMD. Vorolanib works by blocking these proteins. The main goal of this study is to learn how well the study drug works and how safe the study drug is compared with EYLEA® or aflibercept (the comparator in the study).
Please click here for more detailed clinical information on the study.